RESUMO
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) annually publishes the immunisation schedule which, in our opinion, estimates optimal for children resident in Spain, considering available evidence on current vaccines. We acknowledge the effort of the Ministry of Health during the last year in order to optimize the funded unified Spanish vaccination schedule, with the recent inclusion of pneumococcal and varicella vaccination in early infancy. Regarding the funded vaccines included in the official unified immunization schedule, taking into account available data, CAV-AEP recommends 2+1 strategy (2, 4 and 12 months) with hexavalent (DTPa-IPV-Hib-HB) vaccines and 13-valent pneumococcal conjugate vaccine. Administration of Tdap and poliomyelitis booster dose at the age of 6 is recommended, as well as Tdap vaccine for adolescents and pregnant women, between 27-36 weeks gestation. The two-dose scheme should be used for MMR (12 months and 2-4 years) and varicella (15 months and 2-4 years). Coverage of human papillomavirus vaccination in girls aged 11-12 with a two dose scheme (0, 6 months) should be improved. Information for male adolescents about potential beneficial effects of this immunisation should be provided as well. Regarding recommended unfunded immunisations, CAV-AEP recommends the administration of meningococcal B vaccine, due to the current availability in Spanish communitary pharmacies, with a 3+1 scheme (3, 5, 7 and 13-15 months). CAV-AEP requests the incorporation of this vaccine in the funded unified schedule. Vaccination against rotavirus is recommended in all infants. Annual influenza immunisation and vaccination against hepatitis A are indicated in population groups considered at risk.
Assuntos
Esquemas de Imunização , Guias de Prática Clínica como Assunto , Criança , Feminino , Humanos , Lactente , Masculino , Pediatria , Espanha , VacinaçãoRESUMO
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics updates the immunisation schedule every year, taking into account epidemiological data as well as evidence on the safety, effectiveness and efficiency of current vaccines, including levels of recommendation. In our opinion, this is the optimal vaccination calendar for all children resident in Spain. Regarding the vaccines included in the official unified immunization schedule, the Committee emphasizes the administration of the first dose of hepatitis B either at birth or at 2 months of life; the recommendation of the first dose of MMR and varicella vaccine at the age of 12 months, with the second dose at the age of 2-3 years; DTaP or Tdap vaccine at the age of 6 years, followed by another Tdap booster dose at 11-12 years old; Tdap strategies for pregnant women and household contacts of the newborn, and immunization against human papillomavirus in girls aged 11-12 years old with a 2 dose scheme (0, 6 months). The Committee reasserts its recommendation to include vaccination against pneumococcal disease in the routine immunisation schedule, the same as it is being conducted in Western European countries. The recently authorised meningococcal B vaccine, currently blocked in Spain, exhibits the profile of a universal vaccine. The Committe insists on the need of having the vaccine available in communitary pharmacies. It has also proposed the free availability of varicella vaccines. Their efectiveness and safety have been confirmed when they are administred from the second year of life. Vaccination against rotavirus is recommended in all infants. The Committee stresses the need to vaccinate population groups considered at risk against influenza and hepatitis A.
Assuntos
Esquemas de Imunização , Vacinas/administração & dosagem , Adolescente , Algoritmos , Criança , Pré-Escolar , Árvores de Decisões , Humanos , Lactente , Recém-Nascido , EspanhaRESUMO
Meningococcal invasive disease, including the main clinical presentation forms (sepsis and meningitis), is a severe and potentially lethal infection caused by different serogroups of Neisseria meningitidis. Meningococcal serogroup B is the most prevalent in Europe. Most cases occur in children, with a mortality rate of 10% and a risk of permanent sequelae of 20-30% among survivors. The highest incidence and case fatality rates are observed in healthy children under 2-3 years old, followed by adolescents, although it can occur at any age. With the arrival in Spain of the only available vaccine against meningococcus B, the Advisory Committee on Vaccines of the Spanish Association of Paediatrics has analysed its preventive potential in detail, as well as its peculiar administrative situation in Spain. The purpose of this document is to publish the statement of the Committee as regards this vaccination and the access to it by the Spanish population, taking into account that it has been only authorized for people at risk. The vaccine is available free in the rest of Europe for those who want to acquire it, and in some countries and regions it has been introduced into the systematic immunisation schedules. The Committee considers that Bexsero® has a profile of a vaccine to be included in the official schedules of all the Spanish autonomous communities and insists on the need for it to be available in pharmacies for its administration in all children older than 2 months.
Assuntos
Meningite Meningocócica/prevenção & controle , Vacinas Meningocócicas , Neisseria meningitidis Sorogrupo B , Criança , Europa (Continente) , HumanosRESUMO
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) updates the immunisation schedule every year, taking into account epidemiological data as well as evidence on safety, effectiveness and efficiency of vaccines. The present schedule includes levels of recommendation. We have graded, as routine vaccinations, those that the CAV-AEP consider all children should receive; as recommended those that fit the profile for universal childhood immunisation and would ideally be given to all children, but that can be prioritised according to the resources available for their public funding; and as risk group vaccinations those that specifically target individuals in special situations. Immunisation schedules tend to be dynamic and adaptable to ongoing epidemiological changes. Based on the latest epidemiological trends, CAV-AEP recommends the administration of the first dose of MMR and varicella vaccines at age 12 months, with the second dose at age 2-3 years; the administration of DTaP or Tdap vaccine at age 4-6 years, always followed by another Tdap dose at 11-12 years; and the three meningococcal C scheme at 2 months, 12 months and 12 years of age. It reasserts its recommendation to include vaccination against pneumococcal disease in the routine immunisation schedule. The CAV-AEP believes that the coverage of vaccination against human papillomavirus in girls aged 11-12 years must be increased. Universal vaccination against varicella in the second year of life is an effective strategy, and the immediate public availability of the vaccine is requested in order to guarantee the right of healthy children to be vaccinated. Vaccination against rotavirus is recommended in all infants due to the morbidity and elevated healthcare burden of the virus. The Committee stresses the need to vaccinate population groups considered at risk against influenza and hepatitis A. The recently authorised meningococcal B vaccine has opened a chapter of hope in the prevention of this disease. In anticipation of upcoming national and international studies, the Committee recommends the vaccine for the control of disease outbreaks, and insists on the need to be available in pharmacies. Finally, it emphasises the need to bring incomplete vaccinations up to date following the catch-up immunisation schedule.
Assuntos
Esquemas de Imunização , Vacinação/normas , Adolescente , Algoritmos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , MasculinoRESUMO
La inmunosupresión puede ser causa de un falso negativo en la interpretación de la prueba de tuberculina (PT). Se realiza un estudio transversal en una población de niños adoptados e inmigrantes para analizar si la alteración de la inmunidad celular mediada por linfocitos CD4 puede modificar el resultado de la PT. Se incluyó a 1.074 niños (enero de 2003-diciembre de 2008). El estudio de subpoblaciones linfocitarias se efectuó en 884 niños. Un 5,3% tuvo valores de linfocitos CD4 < 25%. No existieron diferencias en el resultado de la PT entre niños con valores normales y patológicos de linfocitos CD4. Varios estudios, incluyendo nuestra serie, han demostrado que no existe una correlación directa entre el valor porcentual de linfocitos CD4 y el resultado de la PT. No obstante, estos resultados deberían confirmarse con series más numerosas y con un mayor porcentaje de niños con valores porcentuales de linfocitos CD4 < 25%
Immunosuppression could be a cause of a false negative tuberculin skin test (TST) result. A cross-sectional study was performed on a population of immigrants and internationally adopted children to analyse whether CD4 cell counts could modify the TST results. A total of 1074 children were included between January 2003 and December 2008. CD4 cell counts were performed on 884 children, in whom 5.3% had CD4 values <25%. There were no differences in TST results among children with normal and pathological CD4 cell counts. Several studies, including this one, have shown that there is no direct association between the CD4 value and the TST results. These results should be confirmed with larger series and with a higher percentage of children with CD4 values <25%
Assuntos
Humanos , Masculino , Feminino , Criança , Teste Tuberculínico/métodos , Imunidade Celular , Tuberculose/diagnóstico , Linfócitos T CD4-Positivos/imunologia , Reações Falso-PositivasRESUMO
Immunosuppression could be a cause of a false negative tuberculin skin test (TST) result. A cross-sectional study was performed on a population of immigrants and internationally adopted children to analyse whether CD4 cell counts could modify the TST results. A total of 1074 children were included between January 2003 and December 2008. CD4 cell counts were performed on 884 children, in whom 5.3% had CD4 values <25%. There were no differences in TST results among children with normal and pathological CD4 cell counts. Several studies, including this one, have shown that there is no direct association between the CD4 value and the TST results. These results should be confirmed with larger series and with a higher percentage of children with CD4 values <25%.
Assuntos
Linfócitos T CD4-Positivos/imunologia , Imunidade Celular/imunologia , Teste Tuberculínico , Adolescente , Adoção , Contagem de Linfócito CD4 , Criança , Pré-Escolar , Estudos Transversais , Emigrantes e Imigrantes , Feminino , Humanos , Lactente , MasculinoRESUMO
INTRODUCTION: Off-label drug use is a common practice in paediatrics. The aim of the present study was to estimate the knowledge of Spaniard paediatricians on off-label use. MATERIAL AND METHODS: Cross-sectional, multicentre, descriptive and national study from July 2012 to March 2013 using an on-line questionnaire on off-label use in children. An e-mail was sent to paediatricians who were members of the Spanish Association of Paediatrics (AEP) or its Regional or Paediatric Specialties Societies. RESULTS: Out of 673 responses were received, 75.1% of Spanish paediatricians knew the meaning of off-label use, 61% of them prescribed medicines outside the conditions authorised in their Summary of Product Characteristics (SPC) and 47% knew of the importance of noting the off-label use in the medical record. However, just under half of paediatricians informed parents, and only 22% wrote it down in the medical record. CONCLUSIONS: Most Spanish paediatricians do not meet current regulations regarding off-label use. This regulation demands: justifying the decisions when off-label use is needed, and to write down in the medical record that, at least an oral consent from the parents has been obtained. This study reveals a fact that Spanish paediatricians must change. Meanwhile, it is a priority to continue with the implementation of consensus and clinical guidelines, to obtain more data on the efficacy and safety of off-label drug use in children, and to incorporate them into the SPC.
Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Uso Off-Label/estatística & dados numéricos , Pediatria , Adulto , Criança , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Espanha , Inquéritos e Questionários , Fatores de TempoRESUMO
Presentamos el Documento de consenso sobre sinusitis de la Sociedad Española de Infectología Pediátrica, la Asociación Española de Pediatría de Atención Primaria, la Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria y la Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial. La sinusitis es una enfermedad de diagnóstico difícil, a menudo no reconocida. Se analiza la etiología, la clínica y los criterios diagnósticos más aceptados, y se realizan recomendaciones terapéuticas acordes con la situación epidemiológica actual. Se propone la amoxicilina por vía oral como tratamiento antibiótico de elección, en dosis de 80 mg/kg al día repartidos cada 8 h. Se indican tratamientos alternativos en casos especiales y en ausencia de eficacia de la amoxicilina. Se revisan las principales complicaciones de la enfermedad (AU)
The Spanish National Consensus (Spanish Society of Pediatric Infectious Diseases, Spanish Association of Primary Care Pediatrics, Spanish Society of Pediatric Outpatient and Primary Care, Spanish Society of Otorhinolaryngology and Cervical-Facial Pathology) on Sinusitisis presented. Rhinosinusitis is a difficult to diagnose and often unrecognised disease. The document discusses the aetiology, the clinical signs and symptoms, and the diagnostic criteria. A proposal for treatment is made based on the epidemiological situation in our country. Oral amoxicillin is the treatment of choice (80 mg/kg/day divided every 8 hours). Alternative treatment is proposed in special cases and when amoxicillin is not sufficient. The main complications are reviewed (AU)
Assuntos
Humanos , Sinusite/diagnóstico , Sinusite/tratamento farmacológico , Antibacterianos/uso terapêutico , Amoxicilina/uso terapêutico , Padrões de Prática Médica , Vacinas Pneumocócicas/administração & dosagem , Resistência Microbiana a MedicamentosRESUMO
Presentamos el Documento de consenso sobre sinusitis de la Sociedad de Infectología Pediátrica (SEIP), la Asociación Española de Pediatría de Atención Primaria (AEPap), la Sociedad Española de Pediatría Extrahospitalaria y de Atención Primaria (SEPEAP) y la Sociedad Española de Otrorrinolaringología Pediátrica (SEORL). La sinusitis es una enfermedad de diagnóstico difícil, a menudo no reconocida. Se analiza la etiología, la clínica y los criterios diagnósticos más aceptados, y se realizan recomendaciones terapéuticas acordes con la situación epidemiológica actual. Se propone la amoxicilina por vía oral como tratamiento antibiótico de elección en dosis de 80 mg/kg/día repartidas cada 8 horas. Se indican tratamientos alternativos en casos especiales y en ausencia de eficacia de la amoxicilina. Se revisan las principales complicaciones de esta entidad (AU)
The Spanish National Consensus (Spanish Society of Pediatric Infectious Diseases,Spanish Association of Primary Care Pediatrics, Spanish Society of Pediatric Outpatient and Primary Care, Spanish Society of Otorhinolaryngology and Cervical-Facial Pathology) on Sinusitisis presented. Rhinosinusitis is a difficult to diagnose and often unrecognised disease. The document discusses the aetiology, the clinical signs and symptoms, and the diagnostic criteria. Aproposal for treatment is made based on the epidemiological situation in our country. Oral amoxicillin is the treatment of choice (80 mg/kg/day divided every 8 hours). Alternative treatment is proposed in special cases and when amoxicillin is not sufficient. The main complications are reviewed (AU)
Assuntos
Humanos , Masculino , Feminino , Criança , Sinusite/diagnóstico , Sinusite/etiologia , Sinusite/terapia , Amoxicilina/uso terapêutico , Seios Paranasais/patologia , Doenças dos Seios Paranasais/epidemiologia , Doenças dos Seios Paranasais/prevenção & controle , Diagnóstico Diferencial , Atenção Primária à Saúde/métodos , Atenção Primária à Saúde/tendências , Atenção Primária à Saúde , Seio Etmoidal/patologia , Resistência a Medicamentos/imunologiaRESUMO
The Spanish National Consensus (Spanish Society of Pediatric Infectious Diseases, Spanish Association of Primary Care Pediatrics, Spanish Society of Pediatric Outpatient and Primary Care, Spanish Society of Otorhinolaryngology and Cervical-Facial Pathology) on Sinusitis is presented. Rhinosinusitis is a difficult to diagnose and often unrecognised disease. The document discusses the aetiology, the clinical signs and symptoms, and the diagnostic criteria. A proposal for treatment is made based on the epidemiological situation in our country. Oral amoxicillin is the treatment of choice (80mg/kg/day divided every 8hours). Alternative treatment is proposed in special cases and when amoxicillin is not sufficient. The main complications are reviewed.
Assuntos
Sinusite/diagnóstico , Sinusite/terapia , Amoxicilina/uso terapêutico , Antibacterianos/uso terapêutico , Criança , Protocolos Clínicos , Humanos , Sinusite/etiologiaRESUMO
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) updates the immunisation schedule every year, taking into account epidemiological data as well as evidence on the safety, effectiveness and efficiency of vaccines. The present schedule includes levels of recommendation. We have graded as routine vaccinations those that the CAV-AEP consider all children should receive; as recommended those that fit the profile for universal childhood immunisation and would ideally be given to all children, but that can be prioritised according to the resources available for their public funding; and as risk group vaccinations those that specifically target individuals in situations of risk. Immunisation schedules tend to be dynamic and adaptable to ongoing epidemiological changes. Nevertheless, the achievement of a unified immunisation schedule in all regions of Spain is a top priority for the CAV-AEP. Based on the latest epidemiological trends, CAV-AEP follows the innovations proposed in the last year's schedule, such as the administration of the first dose of the MMR and the varicella vaccines at age 12 months and the second dose at age 2-3 years, as well as the administration of the Tdap vaccine at age 4-6 years, always followed by another dose at 11-14 years of age, preferably at 11-12 years. The CAV-AEP believes that the coverage of vaccination against human papillomavirus in girls aged 11-14 years, preferably at 11-12 years, must increase. It reasserts its recommendation to include vaccination against pneumococcal disease in the routine immunisation schedule. Universal vaccination against varicella in the second year of life is an effective strategy and therefore a desirable objective. Vaccination against rotavirus is recommended in all infants due to the morbidity and elevated healthcare burden of the virus. The Committee stresses the need to vaccinate population groups considered at risk against influenza and hepatitis A. Finally, it emphasizes the need to bring incomplete vaccinations up to date following the catch-up immunisation schedule.
Assuntos
Esquemas de Imunização , Vacinação , Adolescente , Vacina contra Varicela , Criança , Pré-Escolar , Vacinas contra Hepatite A , Humanos , Lactente , Vacinas contra Influenza , Vacina contra Sarampo-Caxumba-Rubéola , Vacinas Meningocócicas , Neisseria meningitidis Sorogrupo C/imunologia , Vacinas contra Papillomavirus , Vacinas Pneumocócicas , Vacinas contra RotavirusRESUMO
Se presenta el documento de consenso sobre otitis media aguda (OMA) de la Sociedad de Española Infectología Pediátrica (SEIP), Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Sociedad Española de Urgencias Pediátricas (SEUP) y de la Asociación Española de Pediatría de Atención Primaria (AEPAP).Se analizan la etiología de la enfermedad y los posibles cambios de esta después de la introducción de la vacunas antineumocócicas 7-valente, 10-valente y 13-valente. Se hace una propuesta diagnóstica basada en la clasificación de la otitis media aguda en confirmada o probable. Se considera OMA confirmada si hay coincidencia de 3 criterios: comienzo agudo, signos de ocupación del oído medio (u otorrea) y signos o síntomas inflamatorios, como otalgia o intensa hiperemia timpánica y OMA probable cuando existan solo 2 criterios. Se propone como tratamiento antibiótico de elección la amoxicilina oral a 80mg/kg/día repartido cada 8 h. El tratamiento con amoxicilina-ácido clavulánico a dosis de 80mg/kg/día se indica si el niño es menor de 6 meses, en lactantes con clínica grave (fiebre>39°C o dolor muy intenso), cuando haya historia familiar de secuelas óticas por OMA o un fracaso terapéutico de la amoxicilina(AU)
This is the consensus document on acute otitis media (AOM) of the Sociedad Española de Infectología Pediatrica (SEIP), Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Sociedad Española de Urgencias Pediátricas (SEUP) and Asociación Española de Pediatría de Atención Primaria (AEPAP). It discusses the aetiology of the disease and its potential changes after the introduction of the pneumococcal 7-valent, 10-valent and 13-valent vaccines. A proposal is made based on diagnostic classification of otitis media as either confirmed or likely. AOM is considered confirmed if 3 criteria are fulfilled: acute onset, signs of occupation of the middle ear (or otorrhea) and inflammatory signs or symptoms, such as otalgia or severe tympanic hyperaemia. Oral amoxicillin is the antibiotic treatment of choice (80mg/kg/day divided every 8hours). Amoxicillin-clavulanate (80mg/kg/day) is indicated in the following cases: when the child is under 6 months, in infants with severe clinical manifestations (fever>39°C or severe pain), there is family history of AOM sequels, and after amoxiciline treatment failure(AU)
Assuntos
Humanos , Masculino , Feminino , Criança , Otite Média/diagnóstico , Otite Média/terapia , Amoxicilina/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Haemophilus influenzae/isolamento & purificação , Dor de Orelha/complicações , Dor de Orelha/diagnóstico , Dor de Orelha/etiologia , Otite Média/tratamento farmacológico , Otite Média/etiologia , Resistência a Medicamentos/fisiologia , Dor de Orelha/tratamento farmacológico , Ibuprofeno/uso terapêutico , Acetaminofen/uso terapêuticoRESUMO
This is the consensus document on acute otitis media (AOM) of the Sociedad Española de Infectología Pediatrica (SEIP), Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Sociedad Española de Urgencias Pediátricas (SEUP) and Asociación Española de Pediatría de Atención Primaria (AEPAP). It discusses the aetiology of the disease and its potential changes after the introduction of the pneumococcal 7-valent, 10-valent and 13-valent vaccines. A proposal is made based on diagnostic classification of otitis media as either confirmed or likely. AOM is considered confirmed if 3 criteria are fulfilled: acute onset, signs of occupation of the middle ear (or otorrhea) and inflammatory signs or symptoms, such as otalgia or severe tympanic hyperaemia. Oral amoxicillin is the antibiotic treatment of choice (80mg/kg/day divided every 8hours). Amoxicillin-clavulanate (80mg/kg/day) is indicated in the following cases: when the child is under 6 months, in infants with severe clinical manifestations (fever>39°C or severe pain), there is family history of AOM sequels, and after amoxiciline treatment failure.
Assuntos
Otite Média/diagnóstico , Otite Média/tratamento farmacológico , Doença Aguda , Algoritmos , Antibacterianos/uso terapêutico , Criança , Humanos , Otite Média/microbiologiaRESUMO
El tratamiento inicial de las infecciones del tracto urinario (ITU) es empírico por lo que es prioritario conocer la resistencia antibiótica de los microorganismos más frecuentes en una población. Además, tras la sospecha de pielonefritis aguda se debe descartar la presencia de cicatriz renal que puede dar lugar a complicaciones posteriores. Presentamos un estudio longitudinal y retrospectivo de todos los menores de 14 años diagnosticados de ITU desde el 1 de enero del 2009 hasta el 31 de diciembre del 2009. Se analizaron los datos de sensibilidad a antimicrobianos de los patógenos urinarios más importantes, el seguimiento posterior y la presencia de cicatrices. Las bacterias aisladas con mayor frecuencia fueron: Escherichia coli (80%) Proteus mirabillis (9,7%) y Klebsiella pneumoniae (4,2%). En el antibiograma, E. coli presentó una alta sensibilidad frente a fosfomicina (99,1%), cefotaxima (98,2%) cefuroxima (97,3%) y gentamicina (95,6%). La sensibilidad obtenida frente a amoxicilina-clavulánico fue del 83,2%, mientras que la obtenida frente a cotrimoxazol fue del 78,9%.Se encontraron cicatrices pospielonefríticas en el 19% de los pacientes con ITU febril, 17% de los no ingresados y 20% de los ingresados(AU)
The initial treatment of the urinary tract infections (UTI) is empirical and it is a priority to determine the antibiotic resistance of most common germs in a population. Furthermore, due to the suspicion of acute pyelonephritis the presence of renal scarring should be ruled out as this may lead to further complications. A retrospective longitudinal study was performed on all children under 14 years diagnosed with UTI from January 1 2009 to December 31 2009. The in vitro susceptibility to the most important urinary pathogens was analysed, along with the presence of scars, and a subsequent follow-up. The most frequently isolated bacteria were E. coli (80%), P. mirabilis (9.7%) and K. pneumoniae (4.2%). In the antibiogram, E coli showed a high sensitivity to fosfomycin (99.1%), cefotaxime (98.2%) cefuroxime (97.3%) and gentamicin (95.6%). The sensitivity obtained against amoxicillin-clavulanate was 83.2%, while that obtained against cotrimoxazole was 78.9%.Post-pyelonephritis scars were found in 19% of patients with febrile UTI, 17% out-patients and 20% of those admitted(AU)
Assuntos
Humanos , Masculino , Feminino , Criança , Infecções Urinárias/diagnóstico , Testes de Sensibilidade Microbiana/métodos , Escherichia coli/isolamento & purificação , Proteus mirabilis/isolamento & purificação , Klebsiella pneumoniae/isolamento & purificação , Leucocitose/complicações , Leucocitose/diagnóstico , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Ampicilina/uso terapêutico , Produtos com Ação Antimicrobiana , Infecções Urinárias/microbiologia , Estudos Longitudinais/métodos , Estudos Longitudinais , Estudos Retrospectivos , Testes de Sensibilidade Microbiana , Testes de Sensibilidade Microbiana/tendências , Cicatriz/complicações , Pielonefrite/complicações , Pielonefrite/diagnósticoRESUMO
No disponible
Assuntos
Humanos , Masculino , Criança , Febre Reumática/diagnóstico , Artrite Reativa/diagnóstico , Artralgia/etiologia , Diagnóstico DiferencialRESUMO
After being virtually eradicated in Europe, thousands of cases of measles in the population of Spanish origin have appeared in the last 3 years. We describe the cases diagnosed in the north of Madrid between January and June 2011. A total of 22 cases are reported, 18 of them grouped in 2 outbreaks (2 nurseries). The primary attack rate was 29% in the main outbreak. All cases were in unvaccinated patients (median = 14 months). Genotype D4 was predominant (95%). There was a 45% complication rate and 45% were admitted to hospitals. The Public Health Service recommended isolating cases and vaccinating susceptible contacts in advance. Health Centres established a specific protocol to respond to suspected cases. The Measles vaccination has been brought forward from 15 to 12 months in Madrid. Measles is a re-emerging disease in Europe. The coordinated management between public health and health facilities is essential to limiting outbreaks.
Assuntos
Surtos de Doenças , Sarampo/epidemiologia , Humanos , Lactente , Estudos Prospectivos , Estudos Retrospectivos , Espanha/epidemiologia , Saúde da População UrbanaRESUMO
El Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP) actualiza anualmente el calendario de vacunaciones teniendo en cuenta tanto aspectos epidemiológicos, como de efectividad y eficiencia de las vacunas. El presente calendario incluye grados de recomendación. Se han considerado como vacunas sistemáticas aquellas que el CAV-AEP estima que todos los niños deberían recibir; como recomendadas las que presentan un perfil de vacuna sistemática en la edad pediátrica y que es deseable que los niños reciban, pero que pueden ser priorizadas en función de los recursos para su financiación pública; y dirigidas a grupos de riesgo aquellas con indicación preferente para personas en situaciones de riesgo. Los calendarios de vacunaciones tienen que ser dinámicos y adaptarse a los cambios epidemiológicos que vayan surgiendo, pero el CAV-AEP considera como objetivo prioritario la consecución de un calendario de vacunación único para toda España.Teniendo en cuenta los últimos cambios en la epidemiología de las enfermedades, las principales novedades propuestas en este calendario son la administración de la primera dosis de las vacunas triple vírica y varicela a los 12 meses (12-15 meses) y la segunda dosis a los 2-3 años, así como la administración de la vacuna Tdpa a los 4-6 años siempre acompañada de otra dosisa los 11-14 años. El CAV-AEP estima que deben incrementarse las coberturas de vacunación frente al papiloma virus humano en las niñas de 11 a 14 años. Se reafirma en la recomendación de incluir la vacunación frente al neumococo en el calendario de vacunación sistemática. La vacunación universal frente a la varicela en el segundo año de vida es una estrategia efectiva y por tanto un objetivo deseable. La vacunación frente al rotavirus, dada la morbilidad y la elevada carga sanitaria, es recomendable en todos los lactantes. Se insiste en la necesidad de vacunar frente a la gripe y la hepatitis A a todos los que presenten factores de riesgo para dichas enfermedades. Finalmente, se insiste en la necesidad de actualizar las vacunaciones incompletas con las pautas de vacunación acelerada (AU)
The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (CAVAEP) updates the immunization schedule every year, taking into account epidemiological data as well as evidence on the effectiveness and efficency of vaccines.The present schedule includes grades of recommendation. We have graded as routine vaccinations those that the CAV-AEP believes all children should receive; as recommended those that fit the profile for universal childhood immunization and would ideally be given to all children, but that can be prioritized according to the resources available for their public funding; and as risk group vaccinations those that specifically target individuals in situations of risk. Immunization schedules tend to be dynamic and adaptable to on going epidemiological changes. Nevertheless, the achievement of a unified immunization schedule in all regions of Spainis a top priority for the CAV-AEP. Based on the latest epidemiological trends, the main changes introduced to the schedule are the administration of the first dose of the MMR and the varicella vaccines at age 12 months(12---15 months) and the second dose at age 2---3 years, as well as the administration of the Tdap vaccine at age 4---6 years, always followed by another dose at 11---14 years of age.The CAV-AEP believes that the coverage of vaccination against human papilloma virus in girls aged 11---14 years must increase. It reasserts its recommendation to include vaccination against pneumococcal disease in the routine immunization schedule. Universal vaccination against varicellain the second year of life is an effective strategy and therefore a desirable objective. Vaccination against rotavirus is recommended in all infants due to the morbidity and elevated healthcare burden of the virus. The Committee stresses the need to vaccinate population groups considered at risk against influenza and hepatitis A. Finally, it emphasizes the need to bring incomplete vaccinations up to date following the catch-up immunization schedule (AU)
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , 51352 , Esquemas de Imunização , Controle de Doenças Transmissíveis/políticas , Espanha , Controle de Doenças Transmissíveis/métodosRESUMO
El Comité Asesor de Vacunas de la Asociación Española de Pediatría emite todos los años, antes del inicio de la temporada estacional de la gripe, unas recomendaciones sobre la vacunación frente a este virus en la edad pediátrica. Este comité sigue considerando que la vacunación antigripal es una actuación especialmente beneficiosa cuando va dirigida a los niños mayores de 6 meses pertenecientes a los grupos de riesgo, así como a sus convivientes. Se insiste en la recomendación de la vacunación antigripal en el personal sanitario que trabaja con niños (AU)
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics establishes annual recommendations on influenza vaccination in childhood before the onset of influenza season. Routine influenza vaccination is particularly beneficial when the strategy isaimed at children older than 6 months of age with high-risk conditions and their home contacts.The recommendation of influenza vaccination in health workers with children is also emphasised (AU)